MAGE-C2/CT10 (E7B8D) XP^® Rabbit mAb (BSA and Azide Free) #16675

Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).

Melanoma-associated antigen-C2/Cancer testis antigen 10 (MAGE-C2/CT10) belongs to the type I MAGE family of proteins. In normal human tissues, MAGE-C2/CT10 expression is nuclear and largely restricted to germline cells of the testis (4). At the molecular level, research studies have demonstrated that MAGE-C2/CT10 physically interacts with and enhances activity of the TRIM28 E3 RING ubiquitin ligase (5,6). MAGE-C2/CT10 has also been shown to interact with and regulate the activity of SCF CRL E3 ubiquitin ligase complexes toward substrates that control cell cycle progression, suggesting a role for MAGE-C2/CT10 in malignant transformation (7). Indeed, MAGE-C2/CT10 is aberrantly expressed in testicular germ cell tumors, prostate carcinoma, hepatocellular carcinoma, and melanoma (8-11). Furthermore, MAGE-C2/CT10 is immunogenic in some tumor types and as a result, there is interest in targeting antigenic epitopes presented in the context of class I MHC alleles using engineered TCRs (12,13).